HCPLive

Accelerated Cognitive Decline Seen With Type 2 Diabetes in Middle Age

 
MONDAY, Jan. 21 (HealthDay News) -- Middle-aged patients with type 2 diabetes show accelerated cognitive decline in information processing speed and executive function, according to a study published online Dec. 28 in Diabetes Care.

To examine the effects of baseline and incident diabetes on cognitive function, Peggy J.J. Spauwen, from Maastricht University in the Netherlands, and colleagues conducted cognitive testing on 1,290 individuals (40 years or older) participating in the Maastricht Aging Study. Testing was performed at baseline and at six and 12 years.

At baseline, 68 participants had type 2 diabetes, while 54 and 57 had incident diabetes at the six- and 12-year follow-up, respectively. Over the 12-year follow-up, the researchers identified significantly larger decline in information-processing speed, executive function, and delayed word recall among those with diabetes at baseline, compared with control subjects. There was no significant difference noted in the decline for immediate word recall. Participants with incident diabetes showed subtle early decrease in information-processing speed only, compared to the controls; however, in other cognitive domains there was no larger decline observed.

"It seems that disease-exposure time plays an important role in the development of cognitive decline. This might provide a window of opportunity for prevention and early treatment of diabetes-related cognitive deficits," the authors write. "For this, it is important to assess cognitive status at an early stage of the disease and on a regular basis."
 

Abstract
Full Text (subscription or payment may be required)


Copyright © 2013 HealthDay. All rights reserved.
 
 

Most Popular

Recommended Reading

Tenofovir alafenamide, which results in 90% lower circulating plasma tenofovir than standard tenofovir disoproxil fumarate, is associated with similar virologic response rates as the standard regimen, but with an improved safety profile.
Combination treatment with daclatasvir and asunaprevir plus interferon/ribavirin had high success rates in a 24-week clinical trial for treatment of hepatitis C in patients coninfected with HIV.
An interferon/ribavirin-free pill that combines two drugs to treat patients with certain genotypes of hepatitis C who are also infected with HIV was found to be highly effective in a 12-week trial, clearing the hepatitis C virus from almost all the patients involved.
Novel second-generation HIV-1 maturation inhibitor shows favorable antiviral activity and safety profile in HIV-1, subtype B-infected subjects
$vAR$